The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 121 - 130
Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk...
MEDICINE, GENERAL & INTERNAL | BASE-LINE | EVENTS | EFFICACY | SAFETY | PEPTIDE-1 RECEPTOR AGONISTS | Myocardial infarction | Heart attacks | Peptides | Control methods | Glucagon | Clinical trials | Cardiovascular disease | Population studies | Cancer therapies | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Glucagon-like peptide 1 | Women | Cerebral infarction | Enzymes | Stroke | Middle age | Diabetes mellitus | Health risks | Hypoglycemia | Risk analysis | Angina pectoris | Disease control | Cholesterol | Thyroid cancer | Agonists | Diabetes | Cardiovascular diseases | Health risk assessment | Elderly
MEDICINE, GENERAL & INTERNAL | BASE-LINE | EVENTS | EFFICACY | SAFETY | PEPTIDE-1 RECEPTOR AGONISTS | Myocardial infarction | Heart attacks | Peptides | Control methods | Glucagon | Clinical trials | Cardiovascular disease | Population studies | Cancer therapies | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Glucagon-like peptide 1 | Women | Cerebral infarction | Enzymes | Stroke | Middle age | Diabetes mellitus | Health risks | Hypoglycemia | Risk analysis | Angina pectoris | Disease control | Cholesterol | Thyroid cancer | Agonists | Diabetes | Cardiovascular diseases | Health risk assessment | Elderly
Journal Article
Physics Letters B, ISSN 0370-2693, 09/2012, Volume 716, Issue 1, pp. 30 - 61
Results are presented from searches for the standard model Higgs boson in proton–proton collisions at and 8 TeV in the Compact Muon Solenoid experiment at the...
CMS | Higgs | Physics | PARTON DISTRIBUTIONS | SEARCH | PHYSICS, NUCLEAR | COLLIDERS | STANDARD MODEL | ELECTROWEAK CORRECTIONS | BROKEN SYMMETRIES | ASTRONOMY & ASTROPHYSICS | QCD CORRECTIONS | PP COLLISIONS | SPECTRUM | MODEL HIGGS-BOSON | PHYSICS, PARTICLES & FIELDS | Analysis | Collisions (Nuclear physics) | Searching | Elementary particles | Decay | Higgs bosons | Standard deviation | Solenoids | Standards | Bosons | Physics - High Energy Physics - Experiment | High Energy Physics - Experiment | PHYSICS OF ELEMENTARY PARTICLES AND FIELDS
CMS | Higgs | Physics | PARTON DISTRIBUTIONS | SEARCH | PHYSICS, NUCLEAR | COLLIDERS | STANDARD MODEL | ELECTROWEAK CORRECTIONS | BROKEN SYMMETRIES | ASTRONOMY & ASTROPHYSICS | QCD CORRECTIONS | PP COLLISIONS | SPECTRUM | MODEL HIGGS-BOSON | PHYSICS, PARTICLES & FIELDS | Analysis | Collisions (Nuclear physics) | Searching | Elementary particles | Decay | Higgs bosons | Standard deviation | Solenoids | Standards | Bosons | Physics - High Energy Physics - Experiment | High Energy Physics - Experiment | PHYSICS OF ELEMENTARY PARTICLES AND FIELDS
Journal Article
European Physical Journal C, ISSN 1434-6044, 05/2015, Volume 75, Issue 5, p. 1
Properties of the Higgs boson with mass near 125 GeV are measured in proton-proton collisions with the CMS experiment at the LHC. Comprehensive sets of...
TRANSVERSE-MOMENTUM | TOP-PAIR | RATIOS | NLO | RESUMMATION | ELECTROWEAK CORRECTIONS | BROKEN SYMMETRIES | HADRON COLLIDERS | LHC | QCD CORRECTIONS | PHYSICS, PARTICLES & FIELDS | Physics - High Energy Physics - Experiment | Physics | High Energy Physics - Experiment
TRANSVERSE-MOMENTUM | TOP-PAIR | RATIOS | NLO | RESUMMATION | ELECTROWEAK CORRECTIONS | BROKEN SYMMETRIES | HADRON COLLIDERS | LHC | QCD CORRECTIONS | PHYSICS, PARTICLES & FIELDS | Physics - High Energy Physics - Experiment | Physics | High Energy Physics - Experiment
Journal Article
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 131 - 138
Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the...
MEDICINE, GENERAL & INTERNAL | BASE-LINE | LIRAGLUTIDE | INCRETIN | CARDIOVASCULAR OUTCOMES | DISEASE | Myocardial infarction | Therapy | Peptides | Glucagon | Cardiovascular disease | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Urine | Creatinine | Cerebral infarction | Stroke | Kidneys | Epidermal growth factor receptors | Diabetes mellitus | Health risks | Risk analysis | Disease control | Agonists | Microvasculature | Diabetes | Kidney diseases | Renal replacement therapy | Gastrointestinal surgery | Cardiovascular diseases | Health risk assessment
MEDICINE, GENERAL & INTERNAL | BASE-LINE | LIRAGLUTIDE | INCRETIN | CARDIOVASCULAR OUTCOMES | DISEASE | Myocardial infarction | Therapy | Peptides | Glucagon | Cardiovascular disease | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Urine | Creatinine | Cerebral infarction | Stroke | Kidneys | Epidermal growth factor receptors | Diabetes mellitus | Health risks | Risk analysis | Disease control | Agonists | Microvasculature | Diabetes | Kidney diseases | Renal replacement therapy | Gastrointestinal surgery | Cardiovascular diseases | Health risk assessment
Journal Article